Picture of Annexin Pharmaceuticals AB (publ) logo

ANNX Annexin Pharmaceuticals AB (publ) Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Annual cashflow statement for Annexin Pharmaceuticals AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-51.2-40.7-44.2-50.5-37.4
Non-Cash Items4.470.1930.1930.1930.193
Other Non-Cash Items
Changes in Working Capital1.74-0.6340.580.0580.24
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-45-41.2-43.4-50.2-36.9
Capital Expenditures0000-0.129
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0-0.260.0960
Change in Net Investments
Cash from Investing Activities0-0.260.0960-0.129
Financing Cash Flow Items-10.3-0.047-2.90.095-1.86
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities76.423.133.645.248.1
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash31.3-18.4-9.7-5.0811.1